prefer nephrectomy. Of the patients with primary metastatic disease and the tumor in place treated with systemic therapy, 20.1% wanted their kidney tumor to be removed. There was no statistically significant difference between patients who had experience with systemic therapy and those who hadn't, answers were also consistent regardless of gender and age.
INTRODUCTION AND OBJECTIVES:
Cytoreductive nephrectomy (CN) for clear cell renal cell carcinoma (RCC) may be undertaken on patients with varying tumor size and metastatic burden. A recent publication reported that the percentage of overall disease resected may predict post-operative survival. We aimed to validate this finding and further explore the importance of number and distribution of metastases.
METHODS: After obtaining IRB approval, we reviewed 68 patients who underwent CN with clear cell histology and had a pre-operative contrast enhanced Computer Tomography (CT) available for review.
CT scans were reviewed with image segmentation analysis software (TerareconÒ). Measurement of all discernable disease, irrespective of size, was performed. The tumor and metastases' RECIST values, volume, compactness, mean attenuation, location and number were measured. Baseline clinicopathological characteristics were recorded.
Tumor volume resected was categorized based on previous publications and their association with outcome was evaluated with Cox regression analyses. Associations between outcome and the residual disease volume, number and site of lesions were also evaluated.
RESULTS: The study cohort included 68 patients with a median age of 58 years (IQR 53 -66); 25% of patients were female. 22% of patients had a pre-operative metastasectomy. 96% of patients had a KPS !80. Median follow-up for survivors was 26 months . 2-and 5-year survival rates were 60% and 16%, respectively.
The median total disease volume was 236cm3 (IQR 95 -522) most of which was confined to the primary tumor (median 98.6%; IQR 89.3 -99.6) ( Figure 1A ).
Published cutoffs of fraction of disease resected (<90%, 90-95% and >95%) did not predict for overall survival in this cohort ( Figure 1B ). On multivariate analysis disease volume >236cm3 (HR 2.16 (CI 1.18 -3.97) p [ 0.01) and number of lesions (HR 2.10 (CI 1.07 -4.11) p [0.03) were statistically significant predictors of overall survival.
CONCLUSIONS: Our findings demonstrate that oligometastatic disease and lower total volume of disease predicted for a better outcome following CN. However, the findings were not significant when using the previously reported cutoffs. Patients with lower volume of disease should be considered more favorably for surgical management.
Source of Funding:
This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748
MP25-15 ATYPICAL PATTERNS AND TIMING OF RECURRENCES AFTER MINIMALLY INVASIVE SURGERY FOR LOCALIZED KIDNEY CANCER
Paul Russo, Kyle Blum*, Robert Motzer, New York, NY INTRODUCTION AND OBJECTIVES: Characterizing the timing and patterns of renal cell carcinoma (RCC) recurrence after nephrectomy is critical for patient counseling, developing surveillance protocols and selection of adjuvant therapies. Our institutional experience indicates that after 60 months, approximately 11% of patients undergoing open kidney surgery for localized renal cancer will recur with all but 1% of these at metastatic sites (PFS of >84%, (Russo, Cancer 2008) . In the last 15 years we have noticed a number of patients treated with minimally invasive surgery (MIS) for RCC who developed unusual patterns and timing of tumor recurrence. Herein we describe the clinical characteristics and outcomes of these patients with such atypical recurrences.
METHODS: Methods: Patients managed at Memorial Sloan Kettering Cancer Center with MIS radical or partial nephrectomy for localized (N0M0) RCC from 2003-2017 who developed atypical recurrences were identified. Atypical recurrences were defined either as early time to recurrence or an unusual intraabdominal site of recurrence. Recurrence free survival (RFS) distribution was calculated using Kaplan-Meier method. Timing and location of recurrences were described.
RESULTS: Of 28 patients identified, 20 (71%) were male, 15 (53%) had clear cell histology, 11 (39%) were radical nephrectomies and 15 (53%) were robotic-assisted. Stage 1, 2 and 3 disease was present in 16 (57%), 3 (11%), and 9 (32%), respectively. 21 (75%) of the initial MIS procedures were performed at academic centers. 16 (57%) patients were initially Stage 1 but progressed to Stage 4 at a median of 9 months. Unusual sites of recurrence included: abdominal carcinomatosis (14%), soft tissue tumor implants (19%), adjacent organs implants including liver, large and small bowel, spleen, omentum (52%), and port-site (15%). Out of 28 patients, 22 (81%) had an additional burden of therapy in the form of either added surgical resections and/or systemic therapies. After a median follow up of 43.5 months, only 5 patients are alive with no evidence of disease.
CONCLUSIONS: Conclusion: In this cohort of localized renal tumor patients treated with MIS, early recurrence of cancer coupled with unusual sites of intraperitoneal disease was observed. The study limitations include possible referral, selection, and reporting biases. Nevertheless, further investigation into the etiology of these unusual patterns of recurrence after kidney cancer MIS is required.
Source of Funding: none

MP25-16
INTRODUCTION AND OBJECTIVES: Developing metastatic renal cell carcinoma (mRCC) is an insidious, iterative process, diagnosable only after metastatic burden is sufficiently large to be detected by contemporary imaging techniques. A recent publication demonstrated unique evolutionary pathways to metastases. We aimed to investigate whether mutations correlated with the metastatic sites at the time of cytoreductive nephrectomy.
METHODS: After obtaining IRB approval, we queried our prospectively maintained database identifying 514 patients who underwent a nephrectomy, with clear cell histology and mRCC prior to surgery or within 90 days post-operatively.
All patients with MSK-IMPACT genetic sequencing were further evaluated. Baseline clinicopathological characteristics, 22 unique metastatic sites and survival outcomes were recorded. Sites were subsequently grouped into thoracic, nodal, bone, abdominal and other. We used Chi-squared and multivariate analyses to test whether mutations were associated with metastatic locations and if this affected patient outcomes.
RESULTS: Our cohort included 110 patients; 77% male with a median survivor follow up of 34 months . The median number of metastatic sites per patient was 2 (IQR: 1-2). Clinicopathological characteristics, disease sites and mutational events are illustrated in Figure 1 .
Patients with oligometastatic disease ( 2 metastatic organs) compared with disseminated disease trended towards improved overall survival (HR 0.61 (CI: 0.33 -1.12) p[ 0.1). TP53 was significantly associated with disseminated disease (71% vs 20%; p[0.008) .
CONCLUSIONS: This study characterized the distribution of mRCC relative to a targeted panel of mutations, demonstrating that TP53 was significantly associated with disseminated metastases. Patients with oligometastatic disease had longer survival after cytoreductive nephrectomy. Investigation is being undertaken into the mutational clonality and whether mutations can improve nomograms for cytoreductive nephrectomy.
